SetPoint Medical today announced FDA Investigational Device Exemption approval to study its proprietary neuroimmune modulation platform for people with relapsing-remitting multiple sclerosis. Valencia, California–based SetPoint plans to initiate a multicenter, randomized, double-blind, sham-controlled pilot study in 2025. The plan is to enroll 60 people across the United States. “We look forward to initiating this pilot […]
multiple sclerosis
10 innovative diagnostic tests to combat diseases
This is an exciting time for medical diagnostics, with recent innovations allowing for faster disease diagnosis than ever before. From cancer to diabetes to heart disease, here are 10 diagnostic tests that could change the game when it comes to catching diseases earlier. Next >>
